Latest filing published 29 Sept 2026 for Kura Oncology, Inc., €42k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Thomas James Doyle in Kura Oncology, Inc. The record holds 12 filings, for trades running from 7 February 2022 to 28 September 2026.
On the market, this insider has only sold: 5 sales, €94k in total. Outside the open market, there are 7 share grants. 2026 to date brings no purchases and 2 sales.
The newest entry dates from 29 September 2026: an open-market sale of €42k, in Kura Oncology, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations